XNYS · OGN
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Organon & Co.

Organon & Co.

PHARMACEUTICAL PREPARATIONS
$13.55

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is OGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Organon & Co.
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
10K
Country
US

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$13.55
Last session
Day high
$13.55
Last session
Day low
$13.55
Last session
Previous close
$13.55
52W high
$13.55
0.00% from high
52W low
$13.55
Market cap
$3.6B
P/E
6.61×
EPS
$2.05
Shares out
262.6M
VWAP
$13.55
Last session
Veridion warehouse edge

Warehouse intelligence for OGN.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

OGN insider activity

Organon & Co.

Score
Coverage building
Pressure
Net buying
Filings
59
Buys / sells
11 / 48
Net value
$1.6M
Insiders
20
Named filers
OP
Ozuah Philip
Insider
Leadership
LR
Leone Deborah R
Insider
Leadership
SR
Sequeira Ramona
Insider
Leadership
Cluster

10 insiders bought in the last 90 days

Net pressure

Net buying: $1.6M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-152026-06-12Ozuah PhilipInsiderbuy$13.4417,85781,141$240KSEC Form 4
2026-06-152026-06-12Leone Deborah RInsiderbuy$13.4417,85781,141$240KSEC Form 4
2026-06-152026-06-12Sequeira RamonaInsiderbuy$13.4417,85739,951$240KSEC Form 4
2026-06-152026-06-12Ezekowitz AlanInsiderbuy$13.4417,85781,141$240KSEC Form 4
2026-06-152026-06-12Patton Cynthia MInsiderbuy$13.4417,85781,141$240KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 54 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

OGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OGN in this window.
Lobbying spend

OGN lobbying filings, year to date.

Registered lobbying filings matched to Organon & Co..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OGN in this window.
Latest news · OGN
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for OGN.
Options
Sovereign unlock shows live options positioning for OGN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.